AKT1 and colorectal carcinoma: Pharmacological studies have shown that CK1α inhibition (D4476) significantly reduces the AKT/phospho-β-catenin (S552) axis in RAS mutant CRC cell lines, and at the same time inhibits autophagic flux in RAS mutant CRC cells.